Insights

Pipeline Partnerships Blueprint Medicines has a robust rare immunology and oncology portfolio with approved medicines in the US and Europe and a broad pipeline focused on mast cell diseases and solid tumors. This creates licensing, co development, or exclusive collaboration opportunities with pharma companies seeking to augment immunology programs expand indications or accelerate clinical progress. Target areas include systemic mastocytosis chronic urticaria and breast cancer, offering potential for joint development asset licensing or regional commercialization rights.

Acquisition Alignment Market signals indicate Sanofi intends to acquire Blueprint Medicines in a multi billion deal, underscoring strategic demand for rare immunology assets. This presents sales opportunities to engage with Sanofi strategy and business development teams to discuss licensing collaboration on late stage programs or post merger portfolio optimization. Consider positioning data packages manufacturing and supply chain capabilities to support integration.

Leadership Outreach Leadership changes create a window to engage at the C suite level. The appointment of a new chief business officer and subsequent executive transitions suggest timing for outreach on strategic partnerships licensing and deal structuring with Blueprint Medicines or its acquiring entity. Craft messages that emphasize rapid deal paths high value milestones and portfolio alignment.

Commercial Scale With two approved medicines in the US and Europe and a scalable research and commercial platform Blueprint Medicines offers opportunities for co commercialization manufacturing partnerships regional market access support and payer engagement. Potential partners include CROs CMOs distributors and payers seeking to accelerate access to rare disease and oncology assets.

Digital Capabilities Blueprint Medicines tech stack includes AWS Salesforce TensorFlow and a data oriented infrastructure. This enables opportunities to offer data analytics real world evidence generation biomarker discovery companion diagnostics development and AI driven trial optimization. Target collaborations with CROs diagnostic developers and pharma sponsors seeking enhanced data capabilities and faster decision making.

Blueprint Medicines Tech Stack

Blueprint Medicines uses 8 technology products and services including Amazon Web Services, WordPress, Salesforce, and more. Explore Blueprint Medicines's tech stack below.

  • Amazon Web Services
    Cloud Hosting
  • WordPress
    Content Management System
  • Salesforce
    Customer Relationship Management
  • Medscape
    Education Management
  • TensorFlow
    Machine Learning
  • PWA
    Miscellaneous
  • Office 365
    Office Suites
  • macOS
    Operating Systems & Computing Languages

Media & News

Blueprint Medicines's Email Address Formats

Blueprint Medicines uses at least 1 format(s):
Blueprint Medicines Email FormatsExamplePercentage
FLast@blueprintmedicines.comJDoe@blueprintmedicines.com
91%
First.Last@blueprintmedicines.comJohn.Doe@blueprintmedicines.com
8%
FL@blueprintmedicines.comJD@blueprintmedicines.com
1%

Frequently Asked Questions

Where is Blueprint Medicines's headquarters located?

Minus sign iconPlus sign icon
Blueprint Medicines's main headquarters is located at 45 Sidney Street Cambridge, Massachusetts 02139 United States. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is Blueprint Medicines's phone number?

Minus sign iconPlus sign icon
You can contact Blueprint Medicines's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Blueprint Medicines's stock symbol?

Minus sign iconPlus sign icon
Blueprint Medicines is a publicly traded company; the company's stock symbol is BPMC.

What is Blueprint Medicines's official website and social media links?

Minus sign iconPlus sign icon
Blueprint Medicines's official website is blueprintmedicines.com and has social profiles on LinkedInCrunchbase.

How much revenue does Blueprint Medicines generate?

Minus sign iconPlus sign icon
As of June 2026, Blueprint Medicines's annual revenue is estimated to be $509M.

What is Blueprint Medicines's SIC code NAICS code?

Minus sign iconPlus sign icon
Blueprint Medicines's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Blueprint Medicines have currently?

Minus sign iconPlus sign icon
As of June 2026, Blueprint Medicines has approximately 739 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Medical Officer: D. A.Chief Financial Officer: K. D.Chief Scientific Officer: P. C.. Explore Blueprint Medicines's employee directory with LeadIQ.

What industry does Blueprint Medicines belong to?

Minus sign iconPlus sign icon
Blueprint Medicines operates in the Biotechnology Research industry.

What technology does Blueprint Medicines use?

Minus sign iconPlus sign icon
Blueprint Medicines's tech stack includes Amazon Web ServicesWordPressSalesforceMedscapeTensorFlowPWAOffice 365macOS.

What is Blueprint Medicines's email format?

Minus sign iconPlus sign icon
Blueprint Medicines's email format typically follows the pattern of FLast@blueprintmedicines.com. Find more Blueprint Medicines email formats with LeadIQ.

How much funding has Blueprint Medicines raised to date?

Minus sign iconPlus sign icon
As of June 2026, Blueprint Medicines has raised $1.3B in funding. The last funding round occurred on Jun 30, 2022 for $1.3B.

When was Blueprint Medicines founded?

Minus sign iconPlus sign icon
Blueprint Medicines was founded in 2011.

Blueprint Medicines

Biotechnology ResearchMassachusetts, United States501-1000 Employees

Blueprint Medicines, a Sanofi company, is a fully integrated global biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a proven track record of success with two approved medicines in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including systemic mastocytosis and chronic urticaria, breast cancer and other solid tumors.

Patients are at the center of our mission. We know that in order to make a difference in their lives, we must create an environment where our employees — also known as the Blue Crew — can do their best work. Our culture of transparency, curiosity and diversity empowers us to draw upon a wide range of backgrounds and perspectives to build a conscientious team dynamic. Ideas come from every member of the Blue Crew, from the executive team to new hires. Each day, our teams commit to approach one another with respect and trust: a simple promise that fosters an inclusive and collaborative spirit.

We care deeply about the communities where we live and work, and we strive to make a profound impact where it matters most. Learn more about who we are and explore our career opportunities at https://www.blueprintmedicines.com/careers/. 

Read our community guidelines: https://www.blueprintmedicines.com/community-guidelines/.

Section iconCompany Overview

Headquarters
45 Sidney Street Cambridge, Massachusetts 02139 United States
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
BPMC
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2011
Employees
501-1000

Section iconFunding & Financials

  • $1.3B

    Blueprint Medicines has raised a total of $1.3B of funding over 9 rounds. Their latest funding round was raised on Jun 30, 2022 in the amount of $1.3B.

  • $500M$1B

    Blueprint Medicines's revenue is estimated to be in the range of $500M$1B

Section iconFunding & Financials

  • $1.3B

    Blueprint Medicines has raised a total of $1.3B of funding over 9 rounds. Their latest funding round was raised on Jun 30, 2022 in the amount of $1.3B.

  • $500M$1B

    Blueprint Medicines's revenue is estimated to be in the range of $500M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.